Amgen
Biotechnology medicines for serious illnesses including oncology and cardiovascular disease Visit website
CONVICTION SCORE
WHY THIS SCORE
Methodology- Wins in the Feed: not measured: no sourced item about this company in the Feed in 90 days
- Orbital launches: not applicable: not an orbital launch provider that has flown
- Revenue growth: 38, +9% a year, trailing twelve months (lower than the quarter)
- Ladder 0: not a named contributor to any rung on the Dew Point ladder
- Own timelines 60: execution velocity Mixed, editorial and ledgered
- Feed: nothing sourced in 90 days (neutral)
- Form 4: 0 open-market purchases, 2 sales outside a 10b5-1 plan, in 90 days (-6)
- Breadth 50: 1 sector
- Scarcity 75: Biotech & Life Support has 4 covered names
No editorial adjustment. A reviewer may move a computed score by up to 10 points with a reason, recorded on the scorecard.
Inputs frozen Sep 8, 2026 from the site's own feeds: the Feed and Form 4 over 90 days, launches over 365 days, revenue over the trailing year. Next review by Dec 7, 2026. The share price and analyst ratings are not inputs.
DETAILS
SECTORS
PEERS
Biotech & Life SupportScore, then day change (live quotes). Nearest by sector, then by score.
HISTORY
ScorecardComputed under RFC-006 from the 2026-09-08 snapshot: Execution 38 (1 lens: revenue), Milestones 30, Signals 44, Coverage 60, weighted 0.40/0.25/0.20/0.15. Replaces the reviewed editorial score; the formula and every input are on the Methodology page. Methodology ↗
The Morning Dew, in your inbox
The daily brief, live quotes and the newest signals, every morning. Plus a Friday recap of the week. Nothing else, ever.